Paradigm Investor Webinar 4 April 2023

Managing Director Mr Paul Rennie, Chief Medical Officer Dr Donna Skerrett, and Global Head of OA Dr Mukesh Ahuja discuss the recent top-line results from the PARA_OA_008 clinical trial assessing 6-month clinical outcomes as well as structural (MRI) and molecular biomarker changes following a 6-week course of treatment with injectable pentosan polysulfate sodium (iPPS/ Zilousul®) compared to placebo in patients with knee osteoarthritis.